Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy

被引:23
作者
Baghi, Mehran
Mack, Martin G.
Hambek, Markus
Bisdas, Sotirios
Muerthel, Ramona
Wagenblast, Jens
Gstoettner, Wolfgang
Vogl, Thomas
Knecht, Rainald
机构
[1] Goethe Univ Frankfurt, Dept ENT Surg, D-60590 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Diagnost & Intervent Radiol, D-60590 Frankfurt, Germany
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2007年 / 29卷 / 02期
关键词
MR tumor volumetry; predicting factors in SCCHN;
D O I
10.1002/hed.20488
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 [耳鼻咽喉科学];
摘要
Background. The purpose was to evaluate the efficacy of tumor volumetry on MRI as predictive of response to treatment with induction chemotherapy, comparing the results with endoscopy. Methods. Fifty patients with advanced squamous cell carcinoma of the head and neck (SSCHN) who underwent MRI volumetry before and after neoadjuvant chemotherapy consisting of docetaxel, cisplatin, and 5-fluorouract (TPF) were included in this study. The tumor volume was calculated by a slice-by-slice evaluation. With the standard software of a workstation, the area of the tumor was measured slice by slice using manual segmentation. To evaluate the efficacy of MRI volumetry, pretreatment volume was compared with pretreatment remission status as evaluated with endoscopy. Results. Forty-five (90%) patients demonstrated a tumor downstaging after chemotherapy. Fourteen (28%) patients showed a complete histologic remission (CR), 31 (62%) patients showed a partial remission (PR). Pretreatment tumor volume was significantly different between patients whose tumor completely responded (CR) and those whose tumor did not completely respond or whose disease was stable or was progressive (p = .00023). We defined a threshold for the pretreatment tumor volume in patients with CR, which was equal to 29.71 cc. Conclusion. We propose that MRI tumor volume analyses can be a useful parameter to predict the response to neoadjuvant chemotherapy in SCCHN. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:104 / 108
页数:5
相关论文
共 22 条
[1]
Andreopoulou E, 2002, ANTICANCER RES, V22, P1903
[2]
Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence? [J].
Bernier, J ;
Cooper, JS .
ONCOLOGIST, 2005, 10 (03) :215-224
[3]
BURGHARDT E, 1992, CANCER, V70, P648, DOI 10.1002/1097-0142(19920801)70:3<648::AID-CNCR2820700318>3.0.CO
[4]
2-R
[5]
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial [J].
Colevas, AD ;
Busse, PM ;
Norris, CM ;
Fried, M ;
Tishler, RB ;
Poulin, M ;
Fabian, RL ;
Fitzgerald, TJ ;
Dreyfuss, A ;
Peters, ES ;
Adak, S ;
Costello, R ;
Barton, JJ ;
Posner, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1331-1339
[6]
Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy [J].
Doweck, I ;
Denys, D ;
Robbins, T .
LARYNGOSCOPE, 2002, 112 (10) :1742-1749
[7]
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer - A phase II feasibility study [J].
Janinis, J ;
Papadakou, M ;
Xidakis, E ;
Boukis, H ;
Poulis, A ;
Panagos, G ;
Lefantzis, D .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (02) :128-131
[8]
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer [J].
Janinis, J ;
Papadakou, M ;
Panagos, G ;
Panousaki, A ;
Georgoulias, V ;
Hatzidaki, D ;
Lefantzis, D ;
Dokianakis, G .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03) :227-231
[9]
Kikuchi S, 2000, ANTICANCER RES, V20, P3669
[10]
Knecht R, 2004, J CLIN ONCOL, V22, p502S